DraxImage, a division of radiopharmaceutical firm Draxis Health of Mississauga, Ontario, and Bristol-Myers Squibb Medical Imaging of North Billerica, MA, have expanded existing partnership agreements for the marketing and distribution of radiopharmaceutical products in Canada.
Under a new five-year agreement, DraxImage products will continue to be marketed directly to hospital-based radiopharmacy departments through a cooperative partnership promoting the two companies’ product lines.
The agreement also provides for DraxImage’s technetium-99m kits, as well as its indium-111 and xenon-133 radioisotopes, to be distributed exclusively through Bristol-Myers Squibb Medical Imaging in Canada. The balance of the firm’s products for nuclear medicine will be marketed on a non-exclusive basis.
By AuntMinnie.com staff writersJuly 2, 2003
Related Reading
Draxis shuffles management, June 3, 2003
DraxImage begins U.S. shipments of I-131 kit, April 3, 2003
Draxis Health reports record earnings, February 6, 2003
DraxImage gets clearance for radiotherapeutic kit, January 29, 2003
Cytogen, Draxis dispute heats up, January 28, 2003
Copyright © 2003 AuntMinnie.com
